Table 4.
Histological and immunohistochemical findings in biopsies from NAFLD patients carrying PNPLA3 I148M variant with or without metabolic syndrome.
| No MetS (n = 16) | MetS (n = 23) | p-value | |
|---|---|---|---|
| NAFLD activity score | 3.19 ± 1.42 | 4.83 ± 1.37 | 0.000 |
| Steatosis | 1.56 ± 1.15 | 1.87 ± 0.81 | 0.168 |
| Lobular inflammation | 0.81 ± 0.75 | 1.39 ± 0.65 | 0.007 |
| Ballooning | 0.81 ± 0.75 | 1.57 ± 0.73 | 0.002 |
| Portal inflammation (%) | 43.7 | 69.6 | 0.100 |
| Fibrosis score | 1.56 ± 0.73 | 2.48 ± 0.90 | 0.001 |
| Ductular Reaction | 0.15 ± 0.09 | 0.56 ± 0.59 | 0.007 |
| EpCAM+ hepatocytes | 0.47 ± 0.51 | 1.05 ± 0.83 | 0.011 |
| Pericentral αSMA+ HSCs | 4.35 ± 4.14 | 6.55 ± 4.78 | 0.080 |
| Portal/septal αSMA+ MFs | 4.77 ± 3.24 | 7.74 ± 5.94 | 0.045 |
| Lobular S100A9+ macrophages | 8.95 ± 5.18 | 7.54 ± 5.05 | 0.212 |
| Portal S100A9+ macrophages | 2.94 ± 1.93 | 5.56 ± 4.01 | 0.020 |
Data are reported as mean ± standard deviation. p value in bold are statistically significant. MetS: metabolic syndrome; HSCs: hepatic stellate cells; MFs, myofibroblasts; αSMA: α smooth muscle actin.